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Objective: This study focused on the preparation of montelukast sodium (MTK) fast release pulmonary targeted microparticles using the spray 
drying technique. 
Methods: The effect of addition of different excipients namely: mannitol, leucine and ovalbumin on the physico-chemical characteristics of MTK 
spray dried powders were investigated. Powder flow properties, drug association efficiency as well as microparticle size and mass median 
aerodynamic diameter (MMAD) were determined. The prepared microparticles were characterized using FT-IR and TGA. The powder 
crystallographic and thermal properties were studied using DSC and X-ray powder diffraction. A twin stage impinger was used to evaluate in vitro 
pulmonary deposition from which the inhalation indices were derived. 
Results: The tested excipients showed no adverse chemical interactions with the drug based on FT-IR. The best inhalation indices were obtained 
with powders spray dried with leucine followed by leucine/mannitol mixtures with MMAD of 1.73±0.08 and 1.36±0.16 and fine particle fraction of 
60.55±1.63 and 52.31±3.52, respectively. The dried powders showed good physico-chemical stability for up to 6 mo storage. 
Conclusion: The developed MTK spray dried particles may offer a good platform for the targeted pulmonary delivery of MTK overcoming the major 
biological barriers. 
Keywords: Montelukast, Spray drying, Microparticles, Pulmonary delivery, Mannitol, Albumin, Leucine. 
 
INTRODUCTION 
The use of targeted pulmonary delivery systems is an effective 
means of delivering active drugs to the respiratory system. 
Presently, there is a particular research interest in pulmonary 
delivery of drugs, not only for local, but also for systemic effect. This 
is primarily due to the important advantages offered by the 
pulmonary route, especially when considering respiratory tract 
diseases [1, 2]. 
Montelukast (MTK), see structure shown in fig.1, is a leukotriene-
receptor antagonist. This class of medication acts by blocking the 
effects of the cysteinyl leukotrienes, the main proinflammatory 
mediators contributing to the pathology of bronchial asthma [3]. 
Asthma is a complex disorder involving genetic predisposition or 
environmental factors. It results in severe structural and functional 
changes in the respiratory zones of the lungs leading to bronchial 
hyper responsiveness and air flow obstruction thereby causing 
serious discomfort [4].  
 
 
Fig. 1: Montelukast chemical structure 
 
MTK is widely used orally in the management of chronic asthma due 
to its unique hybrid anti-inflammatory and bronchodilator effects 
[5]. However, its oral administration has been associated with side 
effects including headache, drowsiness, gastrointestinal 
disturbances, sleep disorders, hyper-sensitivity reactions, and 
increased bleeding tendency with a higher incidence of Churg–
Strauss syndrome [6]. Development of targeted pulmonary delivery 
systems for MTK can increase receptor occupancy, decrease dose, 
maximize the therapeutic benefits while decreasing the occurrence 
of systemic side effects [1]. 
To effectively target the lung, small particles with aerodynamic 
diameter in the range of 2-5 µm are usually preferred [7]. Particles 
larger than 5 µm usually impact in the upper respiratory tract, while 
smaller particles (1-5 µm) deposit by sedimentation under the effect 
of gravity. Very small particles (<0.5 µm) can diffuse by Brownian 
motion in the bronchi, terminal bronchioles and alveoli [8]. 
Meanwhile, in order to achieve rapid infiltration in the airways, deep 
deposition in alveoli, where thinner alveolar epithelium associated 
with alveoli large surface area, is favored. This stems from the fact 
that the epithelial absorption barrier decreases and the absorption 
increases as a function of the particle penetration depth into the 
lung. Furthermore, particles depositing in the bronchioles are 
normally trapped by ciliated cells and moved with the mucus 
blanket where they are typically exhaled as foreign bodies [9, 10].  
In spite of the thin epithelial barrier (0.2 mm) in the alveolar region, 
the freely roaming macrophages that engulf particles by endocytosis 
represent a potential obstacle for the fate of the particles. 
Macrophages can digest them and slowly migrate with their payload 
up and out of the respiratory tract, either along the mucociliary 
escalator or entering (to a lesser degree) the lymphatic system [9]. 
Literature pointed out to several strategies to overcome such 
barrier: coating of microparticles (MPs) with either the endogenous 
naturally occurring lung surfactant (dipalmito-phosphatidyl choline) 
or the hydrophilic polyethylene glycol presented a chemical 
camouflage to the macrophages [11, 12]. The use of nano-in MPs, 
large porous particles or rapidly dissolving particles are examples of 
physical camouflages based on the particle size [13]. Typically, 
macrophages start engulfing the particles within 5 min reaching 
maximum after 30 min as reported in earlier studies [14].  
To evade the impact of respiratory tract barriers and ensure optimal 
delivery to the target site, it is imperative to develop appropriate 
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carriers using biocompatible excipients. Engineering particles with 
aerodynamic properties fulfilling the above criteria had been lately 
the theme of many studies where various preparation methods were 
adopted [13]. Among these methods, the single step spray drying 
procedure has shown great success. Monitoring the spray drying 
parameters, namely: feed concentration, pump flow rate, aspiration 
as well as temperature with careful selection of excipients and 
carriers are the main controlling factors governing the process yield.  
Tailoring the particles aerodynamic properties with mannitol, 
albumin and leucine were the main focus of this study. Mannitol is a 
crystalline, stable spray dried matrix former and has recently been 
approved by regulatory authorities for inhalation use [15, 16]. 
Sugars are known to act as drying protectants during fast removal of 
water by spray or freeze drying [17]. Motivated by its proven ability 
to shape the particles providing respirable powders with high deep 
lung deposition [18, 19], albumin was also suggested as a particle 
shaper additive. As a low density surfactant, leucine was used due its 
previously reported ability to act as a dispersing aid.  
Accordingly, the ultimate goal of the present study was to tailor MTK 
loaded spray dried powders (SDP) for pulmonary administration. 
The effect of the chosen excipients on the physico-chemical 
characteristics and flow properties of the SDP were investigated. In 
vitro pulmonary deposition was characterized using a twin stage 
impinger. 
MATERIALS AND METHODS 
Materials 
Montelukast sodium (MTK): sincerely given by Glaxo Smith-Kline, 
Egypt. L-Leucine: purchased from Fluka Switzerland. Mannitol: from 
El Nasr Pharmaceutical Chemicals (ADWIC), Abo Zaabal, Cairo, 
Egypt. Ovalbumin (grade 2) purchased from Sigma-Aldrich, UK. All 
other chemicals and reagents were of analytical grade. 
Methods 
Microparticles (MPs) preparation 
The drug and excipients were dissolved, each individually, in water 
containing 30% ethanol then mixed together. The prepared 
hydroalcoholic solutions, containing 1% w/v total solids were spray 
dried with a Buchi B-290 mini spray dryer using the following 
parameters: inlet temperature: 80 °C, aspiration rate: 85% and 
pump flow rate: 5%. The resultant outlet temperature was 48±1°C. 
Table 1 shows the composition of the prepared formulae. 
  
Table 1: Composition of MTK loaded spray dried formulae 
Component Formulae composition % (w/w) 
D DM DL DA DML 
MTK 100 50 50 50 50 
Mannitol - 50 - - 25 
Leucine - - 50 - 25 
Ovalbumin - - - 50 - 
 
Powder characterization 
Yield determination  
The yield values of SDP were determined gravimetrically as 
percentage of the original amounts of solid contents used [7]. 
Drug content determination  
For drug content determination, expressed as association efficiency 
(AE) and drug loading capacity, an accurate weight of each SDP 
formula was dissolved in de ionized water containing 30% v/v of 
ethanol. The UV absorbances were measured at the predetermined 
λmax and the drug content in each formula was evaluated from the 
line equation of a previously constructed calibration curve. MTK 
association efficiency, theoretical and actual loading were calculated 
using to equations 1-3. 
Powder flow properties 
The flow properties of the SDP were evaluated by determining the 
bulk and tapped densities, Carr’s compressibility index (CCI), 
Hausner’s ratio (HR) and the angle of repose (Θ).  
For density determination, a certain weight of each SDP was 
introduced into a small volumetric cylinder, the volume was adjusted 
by tapping twice and the volume occupied by the powder was noted 
(bulk volume or Vb). The cylinder was tapped several times (about 
100 times) on a solid surface till constant volume and the new volume 
occupied by the powder was recorded (tapped volume or Vt). The bulk 
and tapped densities were calculated as shown in equations 4 and 5 
[20]. Based on the calculated bulk and tapped densities, Carr's 
compressibility index (CCI) and Hausner's ratio (HR) were also 
calculated as shown in equations 6 and 7 [21]. 
The static angle of repose (Θ) was determined by pouring a certain 
weight of each SDP through a glass funnel on to a flat collection 
surface till the required height (1 cm) was achieved and a cone was 
obtained. The angle to the horizontal surface (angle of repose) was 
calculated as shown in equation 8 [20, 22].  
Particle size measurement and calculation of mass median 
aerodynamic diameter (MMAD)  
The particle size was measured by the wet dispersion method 
(Laser diffraction-Malvern Mastersizer S, UK) using isopropanol as 
anti solvent [7]. The size distribution was expressed in terms of 
D[v,10], D[v,50], D[v,90] and D[4,3] which are the diameters at 10, 
50 and 90 percentile cumulative volume and the volume mean 
diameter, respectively. The span index, defined as the difference 
between 90 and 10% cumulative volumes, divided by the 50% 
cumulative volume, was also recorded. 
 




Theoretical MTK loading capacity = Theoretical MTK amount
Powder weight
∗ 100 ……………. Equation 2 
 
Actual MTK loading capacity = Actual MTK amount
Powder weight
∗ 100 …………………………. Equation 3 
 
Bulk density = Powder weight
Bulk volume
  …………………. Equation 4 
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Tapped density = Powder weight
Tapped volume
  ……………. Equation 5 
 
CCI = (Tapped density−Bulk density)
Tapped density
∗ 100 ………….Equation 6 
 
HR = Tapped density
Bulk density
  …………………………… Equation 7 
 
tan θ = Height (1 cm)
Radius of the circle formed at the base of the cone 
 …………. Equation 8 
  




 ………………. Equation 9 
Where ρ is the mass density of the particle (tapped density), ρa is the unit density (1 g/cm3) and dg is the cumulative geometric volume 50% 
diameter [10, 23]. 
 
Thermogravimetric analysis (TGA)  
The residual water content in selected SDP was determined by 
heating the sample from 30 °C to 150 °C at a rate of 10 °C/min using 
a thermogravimetric analyzer (Perkin Elmer, Pyris I-Wellesley, USA). 
The percentage weight change of the sample was measured as its 
water content was evaporated and was expressed as percent of the 
initial powder weight. 
X-ray powder diffraction (XRPD)  
XRPD was used to determine the presence of crystalline and 
amorphous contents in selected SDP formulations. A Philips PW 
3710 XRPD, operated at 45 kV, 30 mA, and scanning angles of 5 ° to 
45 °, was used to investigate the powder crystal structure.  
Differential scanning calorimetry (DSC)  
DSC analysis was performed to study the thermal properties of 
the pure drug as received and after spray drying with the 
excipients. For the pure drug, an amount of powder (2-3 mg) was 
loaded in an aluminum pan under dynamic nitrogen purged at 
30 mL/min, then heated from room temperature to 200 °C at 10 
°C heating rate, the temperature was held for 15 min after which 
the sample was cooled to 30 °C at 10 °C/min. The temperature 
was hold for 1 min, then the sample was reheated to 200 °C at 10 
°C/min [7]. DSC was studied on selected formulae using only one 
heating cycle from room temperature to 200 °C at 10 °C/min 
heating rate was used.  
Fourrier transform infrared spectroscopy (FT-IR)  
FT-IR spectra of drug, excipients, 1:1 physical mixtures of MTK with 
each excipient and selected SDP formulae were recorded using 
potassium bromide (KBr) disc method. Each sample was gently 
triturated with powdered KBr in a weight ratio of 1:100 and then 
pressed using a hydrostatic press at a pressure of 10 tons for 5 min. 
The disc was placed in the sample holder and was scanned from 
4000 to 450 cm−1. All spectra were recorded at ambient temperature 
under the vacuum to remove air humidity contribution at a 
resolution of 4 cm-1 and 16 times scanning for each measurement to 
obtain an adequate signal to noise ratio.  
In vitro pulmonary deposition  
In vitro pulmonary deposition of selected SDP formulae was 
determined experimentally using a glass twin stage impinger (TSI) 
as previously reported [24]. Briefly, accurately measured volumes (7 
and 30 mL) of collecting solvent (30% ethanol in water) were placed 
in the upper and lower chambers of the impinger, respectively. 
Aliquots of SDP (30 mg) were loaded in size No. 3 hard gelatin 
capsules which were placed each in the dry powder inhaler device 
(Aerolizer®). The capsule was pierced, the inhaler was attached to 
the throat of the impinger and the powder was drawn through the 
TSI at an air flow rate of 60 L/min operated for 2x5 seconds 
aspirations. The capsule was then removed from the device and the 
empty capsule was weighed to find the remaining non delivered 
amount of powder [25]. The device (inhaler) was washed and the 
mouth, throat and device washings were collected in 25 mL 
volumetric flask. The upper impinger stage (stage 1) washings were 
collected in a 50 mL volumetric flask while a 100 mL volumetric 
flask was used for the lower stage (stage 2).  
The upper impingement chamber is designed such that at a flow rate 
of 60 L/min through the impinger, the particle cut-off is 6.4 µm. 
Particles, smaller than 6.4 µm, pass into the lower impingement 
chamber and constitute the respirable fraction or fine particle 
fraction (FPF). The emitted fraction (EF), defined as the percent of 
total loaded powder mass exiting the capsule [7], was determined 
gravimetrically as follow:  
 
EF = (m FULL−m empty)
m powder
∗ 100 …………….. Equation 10 
Where EF is the emitted fraction, m full and m empty are the masses 
of the capsules before and after simulating the inhalation 
respectively and m powder is the mass of the powder.  
The fine particle fraction (FPF) was calculated as ratio of FPD to the 
emitted dose; where fine particle dose (FPD) < 6.4  μm aerodynamic 
diameter at a flow rate of 60 L/min was defined as the mass of drug 
deposited in the lower stage of the TSI [26].  
 FPF = S2
EF
 …………………. Equation 11 
The Effective inhalation index was calculated as follow [27]:  
EI = √EF ∗ S2 ……………………. Equation 12  
Where EF is the fraction % emitted from the inhalation system, and 
S2 is the fraction % distributed to stage 2 of the TSI. The UV 
absorbance of each collected fraction was measured and the drug 
present at each stage was calculated from a previously constructed 
calibration curve. 
In vitro release study  
An accurately weighed amount of selected SDP corresponding to 
2.5 mg drugs was added to 250 mL of 0.03M phosphate buffer 
solution containing 30% ethanol to allow for sink conditions [28]. 
The flasks were placed in a shaking water bath at 30 strokes/min 
at a temperature of 37±0.5 °C. Samples were taken at different 
time intervals (2, 5 and 15 min), centrifuged and the supernatants 
were analyzed for their drug content spectrophotometrically using 
a previously constructed calibration curve in the same medium. 
Stability study  
Samples of selected SDP formulae were reanalyzed for their total 
drug content and in vitro pulmonary deposition using the TSI after 
3 and 6 mo of storage in desiccators at room temperature (25±2 
°C) [29].  
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Statistical analysis  
All data are expressed as mean of three determinations±standard 
deviation (s. d.). The experimental data were analyzed statistically 
using Graph Pad Prism program by which either the student's t test 
(when comparing means of two groups) or by analysis of variance 
(ANOVA, for more than two groups). Differences were considered 
significant at p≤ 0.05. 
RESULTS AND DISCUSSION 
Yield, drug association efficiency and loading capacity 
Spray drying MTK, without any additives, yielded a powder which 
tended to agglomerate following spray drying. Clumps were noticed 
within two days after preparation and storage in desiccators. This 
could be explained by the effect of fast moisture removal during 
spray drying resulting in a highly hygroscopic product as noted also 
in previous studies [30].  
Another possible explanation could be the crystallization that might 
occur during storage of amorphous SDP, causing stickiness and 
aggregation [31]. Hence, to overcome MTK agglomeration, the use of 
additives was tried.  
Table 2 depicts that 72.4±2.45 % of the drug amount was recovered 
following spray drying its hydroalcoholic solution free from any other 
additive. Addition of excipients in a concentration of 50% increased the 
yield significantly (p≤ 0.05) in case of mannitol, leucine and 
mannitol/leucine mixture with 83.07±1.33, 90.4±1.65 and 86.70±0.95% 
respective yield values for formulae DM, DL and DML. Similarly, the 
effect of leucine and mannitol in improving SDP yields had been reported 
previously by other investigators [32]. On the contrary, ovalbumin 
caused a significant decrease (p≤ 0.05) in yield value which reached 
50.69%. Sticking of the powder on the cyclone wall noticed during spray 
drying the drug with ovalbumin accounted for the high loss. Moreover, 
clumping and agglomeration occurred following co-spray drying the 
drug with ovalbumin at this concentration (50% w/w). 
  
Table 2: Yield values, drug association efficiency and loading capacity in the spray dried powders formulae 
Formula code Yield values (%) AE (%) MTK loading (%w/w) 
Theoretical Actual 
D 72.40±2.45 - 100 - 
DM 83.07±1.33 99.89±2.9 50 49.94±1.45 
DL 90.40±1.65 94.75±0.81 50 47.37±0.40 
DA 50.69±4.83 96.72±1.15 50 48.36±0.57 
DML 86.70±0.95 104.66±1.80 50 52.33±0.90 
*Results are mean of three determinations±s. d.-: Not determined. 
 
High association efficiencies, exceeding 90%, were achieved with all 
formulae. The assayed MTK contents were very close to the 
theoretical values inferring that only small amounts of drug were 
lost during the preparation process.  
Powder flow properties  
As shown in table 3, Formula DM prepared with 50% mannitol, 
exhibited higher bulk and tapped densities than DL and DML. As 
expected, higher densities were obtained after tapping and the 
increase was higher in case of the former formula denoting larger 
inter particular voids compared to the other 2 formulae.  
The decrease in density noted after replacing a part of mannitol with 
leucine stands behind the preferred use of the later during spray 
drying of powders intended for pulmonary administration.  
As a low density surfactant, it precipitated early on the surface of the 
evaporating droplet improving the particle de-agglomeration and 
reducing the bulk density of drug/carrier particles [31]. 
  
Table 3: Flow properties of MTK loaded spray dried formulae 
Code Bulk density (g/cm3) Tapped density (g/cm3) Carr's index (%) Hausner’s ratio Angle of repose (°) 
DM 0.35±0.015 0.59±0.034 40.36±1.30 1.67±0.03 46.55±0.58 
DL 0.14±0.002 0.18±0.005 31.95±0.85 1.47±0.01 40.81±0.41 
DML 0.24±0.008 0.38±0.014 37.60±0.45 1.60±0.01 43.60±0.68 
*Results are mean of three determinations±SD. 
 
The observed CCI, HR and angle of repose ranged from 31.95 to 
40.36%, 1.47 to 1.67 and 40.5 to 46.55°, respectively. It is 
worthy to mention here, that because of the small amounts of 
powder and the work on the small scale, the differences between 
the powers could not be clearly seen and almost all formulae 
showed cohesiveness based on the classification mentioned in 
literature [33-35].  
It should also be pointed out that it was not possible to 
accurately determine the flow properties of the drug spray dried 
alone or with ovalbumin due to the previously explained 
agglomeration yielding false results for flow properties. The best 
flow properties expressed were achieved with formula DL 
prepared with 50% leucine.  
Particle size and mass median aerodynamic diameter  
From table 4, we could observe that 90% of the particles were less 
than 5 µm indicating suitability for pulmonary administration [36]. 
Due to the low density of the particles, the theoretical MMAD was 
found to be lower than their geometric particle size. 
Thermogravimetric analysis (TGA)  
TGA was performed on representative formulae DM and DL and no 
residual water was found in both formulae. None of the formulae 
exceeded 3% of water, the upper limit of moisture characterizing a 
dry powder as identified in previous studies [37]. Hence, the 
selected spray drying parameters was suitable to produce dried 
powders with minimal residual moisture. 
X-ray powder diffraction  
In accordance with previously reported data, the X-ray 
diffractogram of pure MTK, fig. 2a, reveals diffused peaks 
characteristic of its very low crystallinity [38]. On the other hand, 
the diffractogram of leucine, fig. 2b, shows characteristic peaks at 5ᶱ, 
25ᶱ and 31ᶱ indicating high crystallinity. Similarly, the X-ray 
diffractogram of mannitol, fig. 2c, reveals crystalline peaks at 10.56, 
14.71ᶱ denoting the presence of beta polymorph. Other lower 
intensity peaks could also be detected in mannitol diffractogram at 
19, 24, 40 and 45ᶱ. From fig. 2d we could conclude the presence of 
albumin in the amorphous form which could be the reason of the 
agglomeration observed in DA formula. 
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Table 4: Particle size and MMAD of MTK loaded spray dried formulae 
Code D[4,3] (µm) Span Distribution percentile volume (µm) MMAD (µm) 
10% 50% 90% 
DM 2.26±0.11 1.91±0.08 0.54±0.01 1.98±0.06 4.32±0.28 0.59±0.03 
DL 3.17±0.38 1.60±0.31 0.59±0.16 3.22±0.61 5.64±0.18 1.73±0.08 
DML 2.53±0.03 2.06±0.03 0.57±0.01 2.16±0.01 5.01±0.09 1.36±0.16 
Results are mean of three determinations±SD MMAD: mass median aerodynamic diameter and D [4, 3]: Volume mean diameter. 
 
Spray dried formula DM diffractogram, fig. 2e, shows mannitol 
characteristic peaks at 19, 24. 40, 45 with lower intensity that the 
pure excipient. Mixing with the drug followed by spray drying can 
justify the noted decrease in peaks intensity [39]. The change of the 
position of some peaks might denote the crystallization of mannitol 
into another polymorph. This crystallization had already been 
reported in many references and depended on the spray drying 
conditions [40].  
Similarly, leucine characteristic peaks can still be seen after 
spray drying with the drug as shown in fig. 2f. Previous studies 
postulated that above a threshold level, 10% leucine 
concentration in that work, leucine crystallinity peaks were still 
seen after spray drying [41]. We can thus conclude that the 
produced spray dried powders (formulae DM and DL) were 
crystalline in nature probably due to the presence of leucine and 
mannitol at 50% concentration.  
 
 
Fig. 2: X-ray diffractograms of pure (a) drug, (b) leucine, (c) mannitol, (d) albumin and formulae (e) DM and (f) DL 
 
Differential scanning calorimetry (DSC)  
In order to study the thermal properties of the drug, it deemed 
necessary to use two heating cycles. The first one was used to get rid 
of the drug associated water as the result of its highly hygroscopic 
nature [42, 43]. In the second heating cycle, in fig. 3, the broad water 
endotherm, seen before 100°C, disappeared due to the volatilization 
of water and only one small broad endotherm was seen at 149°C. 
This peak corresponded to the drug melting previously mentioned in 
literature[44].  
As shown in fig. 4, mannitol exhibits a single sharp endothermic 
peak at about 171°C corresponding to its melting point [45]. This 
peak can also be seen in DM containing 50 % of mannitol but with a 
much lower intensity. Furthermore, in spite of the spray drying 
process, the obtained powder (DM) showed some crystallinity 
attributed to the presence of mannitol at this high concentration 
(50%) confirming the results obtained from XRPD. Leucine melting 
endotherm was not shown in its thermogram as it normally melts at 
296 °C, higher than the used temperature range in this study [46]. A 
similar observation could also be seen in case of DL. 
Fourrier transform infrared spectroscopy (FT-IR)  
To investigate the interaction between the components of SDP, FT-IR 
studies were conducted. MTK pure drug, fig. 5, shows the bond 
vibrations at 3355 cm-1 (COOH stretching), 3058.3 cm-1 (aromatic CH 
stretching), 2974.3 cm-1 (aliphatic CH stretching) [47]. Other peaks 
observed at 1636.3 cm-1 corresponded to C=O stretching, at 1562.6 
and 1595 cm-1 are the C-C aromatic stretch, while at 1495 cm-1 
appeared the C-C alkane stretch, 1136 cm-1 C-O stretch of alcohol, 
960 cm-1 OH bend and 697.8 cm-1 sharp peak corresponded to =C-H 
bend of alkenes. 
 
 
Fig. 3: DSC thermogram of MTK as received 
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Fig. 4: DSC thermograms of MTK, excipients, MTK/physical 
mixtures and selected spray dried formulae 
 
Mannitol FT-IR spectrum, fig. 5, shows the free alcoholic OH stretch 
between 3200-3500 cm-1, CH stretch of alkane peaks between 2906-
2970 cm-1 could also be depicted. A medium peak at 1459 cm-1 
attributed to CH bending, two sharp peaks at 1019 cm-1 and 1082 cm-1 
corresponding to C-O alcoholic stretch could also be seen in the 
spectrum.  
Leucine FT-IR spectrum shows characteristic peaks at 3402 and 
3056 cm-1 corresponding to the asymmetric valence vibrations of 
the ammonium group and the free carboxylic OH broad peak 
respectively. CH alkane stretch could be seen at 2959 and 2871 cm-1, 
while the characteristic peak at 2129 cm-1 corresponded to 
symmetric valence vibration of the ammonium group. 
It could be seen that the spectrum of MTK/mannitol physical 
mixture is a simple superposition of the spectra of both 
components. In the spray dried formula DM, mannitol peaks are 
more prominent and of higher intensity than in the physical 
mixture. For leucine containing formulae (physical mixture or 
spray dried), it is obvious that the drug peaks were completely 
masked or merged with leucine bands. To sum up, no 
disappearance nor major shift was noted in the characteristic 
bands of MTK when combined with the selected excipients in the 
spray dried formulae. Hence, no obvious incompatibilities could 
be detected with the chosen additives.  
 
 
Fig. 5: FT-IR spectra of MTK, excipients, their physical mixtures and selected spray dried formulae 
 
In vitro pulmonary deposition 
The effect of the formulation variables on the in vitro pulmonary 
deposition was studied using TSI. The drug percent deposited in 
mouth/throat and device (D/M/T) and in stages 1 and 2 are 
illustrated in fig. 6. The inhalation indices namely ED, FPF and EI 
were calculated and are presented in table 5.  
Early deposition of a large fraction from formula DM was seen in 
D/M/T and in stage 1 probably due to its previously 
demonstrated poor flow characteristics. On the other hand, very 
fluffy fine light particles of formula DL gave this formula the 
chance of travelling deeper in the device, thus deposited in stage 
2. Replacing a part of mannitol with leucine greatly improved the 
stage 2 deposition as well as all inhalation indices as shown in 
DML compared to DM.  
 
Fig. 6: In-vitro pulmonary deposition of MTK spray dried 
formulae using TSI
 
Table 5: Inhalation indices of MTK spray dried formulae 
Code Inhalation indices % 
ED% FPF% EI% 
DM 93.87±3.08 8.87±0.37 27.96±0.52 
DL 88.69±1.95 60.55±1.63 69.02±1.66 
DML 87.78±5.75 52.31±3.52 63.47±3.76 
*Results are mean of three determinations±s. d., ED: emitted dose, FPF: fine particle fraction, EI: effective inhalation index. 
 
In vitro release study  
Fig. 7 shows that MTK dissolved at a faster rate following its spray 
drying releasing 95 % of the drug in 5 min. Similarly, an 
instantaneous release of MTK was seen with the SDP formulae DM, 
DL & DML where 100% release was achieved in less than 15 min. 
This fast release is of special importance when considering 
pulmonary delivery. This does not only provide fast drug onset of 
action but also can guarantee avoidance of uptake and engulfment 
by the rooming alveolar macrophages.  
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Fig. 7: In vitro release study of MTK SD formulae in 0.03M 
phosphate buffer solution containing 30% ethanol at 37 °C and 30 
stroke/min (mean±SD, n = 30). *For formulae composition, refer to 
table 1 
 
Fig. 8: In vitro pulmonary deposition of MTK loaded SDP 
determined using TSI. 
 
Table 6: MTK association efficiency after storage at various times intervals 
Formula Association efficiency (%) at various time intervals  
Fresh 3 Mo 6 Mo 
DM 96.76±0.77 96.24±1.18 95.63±0.66 
DL 94.75±0.81 94.94±0.92 94.86±0.51 
DML 96.54±2.90 96.76±0.76 96.58±0.42 
*Results are mean of three determinations±SD No statistically significant changes in drug association efficiency (table 6) or deposition in TSI (fig. 8) 
with storage could be detected with the selected formulae indicating their stability.  
 
Stability study  
To evaluate the long term stability, the total drug content and the in 
vitro pulmonary deposition for selected formulae, DM, DL and DML), 
were evaluated after storage for three and six months. As shown in 
table 6, the data were compared to those obtained with the freshly 
prepared formulae. 
CONCLUSION 
The ultimate goal of the study was to prepare stable targeted 
pulmonary delivery system of MTK using the spray drying 
technique. To improve the stability of MTK following spray drying, 
hydro alcoholic mixtures of MTK and different excipients were spray 
dried. Ovalbumin produced sticky unstable powders with very low 
yields. Mannitol was found to produce dense particles with small 
particle size, poor flow properties and low respirable fraction. 
Leucine significantly improved flow properties, providing powders 
with high inhalation indices. DSC and X-ray studies revealed the 
crystallinity of the spray dried powders which probably contributed 
to the enhanced stability and flow characteristics of the powders. 
The fast release of the drug and immediate dissolution of the 
powders will be important in avoiding uptake by the highly active 
alveolar macrophages. 
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